Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rigel Pharmaceuticals, Inc. - Common Stock (NQ:RIGL)

35.68 +0.96 (+2.76%)
Streaming Delayed Price Updated: 10:51 AM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rigel Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Shows Explosive Growth, Fits Navellier's 'Little Book' Strategy
Rigel Pharmaceuticals shows explosive growth with 729% EPS growth, 106% revenue surge, and a 119% ROE, making it a top pick for momentum investors. 
Via Chartmill
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Combines High Growth Momentum with Strong Technical Setup
Discover RIGL stock's high growth momentum & strong technical setup. A top pick for investors seeking earnings acceleration & breakout potential. 
Via Chartmill
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Affordable Growth Stock
Rigel Pharmaceuticals (RIGL) is a GARP stock with explosive 729% EPS growth, trading at a deep discount with a P/E of just 7.11. 
Via Chartmill
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A Deep Value Stock with Strong Fundamentals
Rigel Pharmaceuticals (RIGL) presents a strong value investing case with a high valuation score, robust profitability, and impressive revenue growth, trading below intrinsic value. 
Via Chartmill
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Growth Stock on Navellier's Screening Model
Rigel Pharmaceuticals (RIGL) excels in a proven growth stock screening method, showing massive earnings growth, soaring revenue, and a high return on equity. 
Via Chartmill
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
A Preview Of Rigel Pharmaceuticals's Earnings
 
Via Benzinga
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks are being observed in Tuesday's session. 
Via Chartmill
Unusual volume stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
Rigel (RIGL) Q2 Revenue Jumps 176%
Via The Motley Fool
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Aligns Perfectly with Louis Navellier’s Growth Investing Strategy
Louis Navellier’s growth investing strategy highlights stocks like RIGL with strong earnings momentum, rising sales, and profitability, making it a standout pick for investors. 
Via Chartmill
What to Expect from Rigel Pharmaceuticals's Earnings
 
Via Benzinga
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic Data: What's Driving Markets Wednesday?
The three major indices were mostly flat in midday trading Wednesday with the S&P 500 and Nasdaq slightly under the flatline and the Dow Jones up 39 points.  
Via Benzinga
Topics Government Stocks
Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday?
U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions. 
Via Benzinga
Topics World Trade
Earnings Scheduled For March 4, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz
The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam. 
Via Stocktwits
Dow Jumps Over 200 Points, Crude Oil Gains 1.5%
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
From AscellaHealth, LLC
Via GlobeNewswire
RIGL Stock Earnings: Rigel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
RIGL stock results show that Rigel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets. 
Via InvestorPlace
RIGL Stock Earnings: Rigel Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
RIGL stock results show that Rigel Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023
RIGL stock results show that Rigel Pharmaceuticals beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.